105 related articles for article (PubMed ID: 9781646)
1. Mitotic cyclins and cyclin-dependent kinases in melanocytic lesions.
Tran TA; Ross JS; Carlson JA; Mihm MC
Hum Pathol; 1998 Oct; 29(10):1085-90. PubMed ID: 9781646
[TBL] [Abstract][Full Text] [Related]
2. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
3. Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes.
Kallakury BV; Ambros RA; Hayner-Buchan AM; Sheehan CE; Malfetano JH; Ross JS
Int J Gynecol Pathol; 1998 Oct; 17(4):320-6. PubMed ID: 9785132
[TBL] [Abstract][Full Text] [Related]
4. The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: a comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34cdc2.
Kallakury BV; Sheehan CE; Rhee SJ; Fisher HA; Kaufman RP; Rifkin MD; Ross JS
Cancer; 1999 Apr; 85(7):1569-76. PubMed ID: 10193948
[TBL] [Abstract][Full Text] [Related]
5. The significance of Ki-67 proliferative index and cyclin D1 expression of dysplastic nevi in the biologic spectrum of melanocytic lesions.
Lebe B; Pabuççuoğlu U; Ozer E
Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):160-4. PubMed ID: 17525627
[TBL] [Abstract][Full Text] [Related]
6. Cyclin D1 expression in melanocytic lesions of the skin.
Ramirez JA; Guitart J; Rao MS; Diaz LK
Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
[TBL] [Abstract][Full Text] [Related]
7. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions.
Keller-Melchior R; Schmidt R; Piepkorn M
J Invest Dermatol; 1998 Jun; 110(6):932-8. PubMed ID: 9620301
[TBL] [Abstract][Full Text] [Related]
8. Expression of cyclins and cyclin-dependent kinases in smooth muscle tumors of the uterus.
Zhai YL; Nikaido T; Shiozawa T; Orii A; Fujii S
Int J Cancer; 1999 Jun; 84(3):244-50. PubMed ID: 10371341
[TBL] [Abstract][Full Text] [Related]
9. Expression of the G2-M checkpoint regulators cyclin B1 and P34CDC2 in breast cancer: a correlation with cellular kinetics.
Megha T; Lazzi S; Ferrari F; Vatti R; Howard CM; Cevenini G; Leoncini L; Luzi P; Giordano A; Tosi P
Anticancer Res; 1999; 19(1A):163-9. PubMed ID: 10226538
[TBL] [Abstract][Full Text] [Related]
10. Expression of cyclins A and E in melanocytic skin lesions and its correlation with some clinicopathologic features.
Alekseenko A; Wojas-Pelc A; Lis GJ; Wiśniowski Z; Czerwińska M; Niewiara Ł; Litwin JA
Folia Histochem Cytobiol; 2012 Jul; 50(2):263-9. PubMed ID: 22763964
[TBL] [Abstract][Full Text] [Related]
11. Detection of telomerase activity and correlation with mitotic and apoptotic indices, Ki-67 and expression of cyclins D1 and A in cutaneous melanoma.
Miracco C; Pacenti L; Santopietro R; Biagioli M; Fimiani M; Perotti R; Rubegni P; Pirtoli L; Luzi P
Int J Cancer; 2000 Nov; 88(3):411-6. PubMed ID: 11054670
[TBL] [Abstract][Full Text] [Related]
12. Comparison of proliferative activity as assessed by proliferating cell nuclear antigen (PCNA) and Ki-67 monoclonal antibodies in melanocytic skin lesions. A quantitative immunohistochemical study.
Rieger E; Hofmann-Wellenhof R; Soyer HP; Kofler R; Cerroni L; Smolle J; Kerl H
J Cutan Pathol; 1993 Jun; 20(3):229-36. PubMed ID: 8103531
[TBL] [Abstract][Full Text] [Related]
13. Comparison of mitotic cyclins and cyclin-dependent kinase expression in keratoacanthoma and squamous cell carcinoma.
Tran TA; Ross JS; Boehm JR; Carlson JA
J Cutan Pathol; 1999 Sep; 26(8):391-7. PubMed ID: 10551411
[TBL] [Abstract][Full Text] [Related]
14. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical studies of conjunctival nevi and melanomas.
Jakobiec FA; Bhat P; Colby KA
Arch Ophthalmol; 2010 Feb; 128(2):174-83. PubMed ID: 20142539
[TBL] [Abstract][Full Text] [Related]
16. Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions.
Georgieva J; Sinha P; Schadendorf D
J Clin Pathol; 2001 Mar; 54(3):229-35. PubMed ID: 11253137
[TBL] [Abstract][Full Text] [Related]
17. Minichromosome maintenance proteins are useful adjuncts to differentiate between benign and malignant melanocytic skin lesions.
Gambichler T; Shtern M; Rotterdam S; Bechara FG; Stücker M; Altmeyer P; Kreuter A
J Am Acad Dermatol; 2009 May; 60(5):808-13. PubMed ID: 19389522
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase 2 expression in human melanomas and benign melanocytic skin lesions.
Kuźbicki L; Aładowicz E; Chwirot BW
Melanoma Res; 2006 Oct; 16(5):435-44. PubMed ID: 17013093
[TBL] [Abstract][Full Text] [Related]
19. In situ analysis of transforming growth factor-beta s (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma.
Schmid P; Itin P; Rufli T
Carcinogenesis; 1995 Jul; 16(7):1499-503. PubMed ID: 7614683
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of metallopanstimulin/S27 ribosomal protein in melanocytic lesions of the skin.
Santa Cruz DJ; Hamilton PD; Klos DJ; Fernandez-Pol JA
J Cutan Pathol; 1997 Oct; 24(9):533-42. PubMed ID: 9404850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
